A dual inhibitor of platelet-derived growth factor β-receptor and Src kinase activity potently interferes with motogenic and mitogenic responses to PDGF in vascular smooth muscle cells: A novel candidate for prevention of vascular remodeling

Circulation Research

Volumn 85, Issue 1, 1999, Pages 12-22

  Waltenberger, Johannes ^a   Uecker, Andrea ^b   Kroll, Jens ^a   Frank, Hedwig ^a   Mayr, Ulrike ^a   Bjorge, Jeffrey D ^c   Fujita, Donald ^c   Gazit, Aviv ^d   Hombach, Vinzenz ^a   Levitzki, Alexander ^d   Böhmer, Frank D ^b  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c UNIVERSITY OF CALGARY   (Canada)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Atherosclerosis; Coronary artery smooth muscle cell; Platelet derived growth factor receptor; PP1 AGL1872; Restenosis; Tyrphostins

Indexed keywords

FIBROBLAST GROWTH FACTOR RECEPTOR; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN KINASE P60; PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR; VASCULOTROPIN RECEPTOR;

ARTICLE; ATHEROSCLEROSIS; CELL MIGRATION; CELL PROLIFERATION; CELL STRAIN 3T3; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RESTENOSIS; SMOOTH MUSCLE FIBER; TISSUE REGENERATION; VASCULAR SMOOTH MUSCLE;

EID: 0033538676     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.85.1.12     Document Type: Article

References (43)

1. Fantl WJ, Johnson DE, Williams LT. Signalling by receptor tyrosine kinases. Annu Rev Biochem. 1993;62:453-481.
2. Weiss FU, Daub H, Ullrich A. Novel mechanisms of RTK signal generation. Curr Opin Genet Dev. 1997;7:80-86.
3. Gibbs JB, Oliff A. Pharmaceutical research in molecular oncology. Cell. 1994;79:193-198.
4. Levitzki A, Gazit A. Tyrosine kinase inhibition: an approach to drug development. Science. 1995;267:1782-1788.
5. Fry DW. Recent advances in tyrosine kinase inhibitors. Annu Rep Med Chem. 1996;31:151-160.
6. Levitzki A. Targeting signal transduction for disease therapy. Curr Opin Cell Biol. 1996;8:239-244.
7. Kovalenko M, Gazit A. Bohmer A, Rorsman C, Ronnstrand L, Heldin CH, Waltenberger J, Bohmer FD, Levitzki A. Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res. 1994;54:6106-6114.
8. Gazit A, App H, McMahon G, Chen J, Levitzki A, Bohmer FD. Tyrphostins, 5: potent inhibitors of platelet-derived growth-factor receptor tyrosine kinase-structure-activity-relationships in quinoxalines, quinolines, and indole tyrphostins. J Med Chem. 1996;39:2170-2177.
9. Kovalenko M, Ronnstrand L, Heldin CH, Loubtchenkov M, Gazit A, Levitzki A, Bohmer FD. Phosphorylation site-specific inhibition of platelet-derived growth-factor beta-receptor autophosphorylation by the receptor blocking tyrphostin AG1296. Biochemistry. 1997;36:6260-6269.
10. Heldin CH, Westermark B. Platelet-derived growth factor and autocrine mechanisms of oncogenic processes. Crit Rev Oncog. 1991;2:109-124.
11. Strawn LM, Mann E, Elliger SS, Chu LM, Germain LL, Niederfellner G, Ullrich A, Shawver LK. Inhibition of glioma cell growth by a truncated platelet-derived growth factor-beta receptor. J Biol Chem. 1994;269: 21215-21222.
12. Buchdunger E, Zimmermann J, Mett H, Meyer T, Muller M, Regenass U, Lydon NB. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class. Proc Natl Acad Sci U S A. 1995;92: 2558-2562.
13. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
14. Waltenberger J. Modulation of growth factor action: implications for the treatment of cardiovascular diseases. Circulation. 1997;96:4083-4095.
15. Hart CE, Clowes AW. Platelet-derived growth factor and arterial response to injury. Circulation. 1997;95:555-556.
16. Golomb G, Fishbein I, Banai S, Mishaly D, Moscovitz D, Gertz SD, Gazit A, Poradosu E, Levitzki A. Controlled delivery of a tyrphostin inhibits intimal hyperplasia in a rat carotid artery injury model. Atherosclerosis. 1996;125:171-182.
17. Fukumoto Y, Shimokawa H, Kozai T, Kadokami T, Kuwata K, Owada MK, Shiraishi T, Kuga T, Egashira K, Takeshita A. Tyrosine kinase inhibitor suppresses the (re)stenotic changes of the coronary-artery after balloon injury in pigs. Cardiovasc Res. 1996;32:1131-1140.
18. Golomb G, Fishbein I. Tyrphostins, inhibitors of protein-tyrosine kinase, in restenosis. Adv Drug Deliv Rev. 1997;24:53-62.
19. Fukui R, Shibata N, Kohbayashi E, Amakawa M, Furutama D, Hoshiga M, Negoro N, Nakakouji T, Ii M, Ishihara T, Ohsawa N. Inhibition of smooth-muscle cell-migration by the p21 cyclin-dependent kinase inhibitor (cip1). Atherosclerosis. 1997;132:53-59.
20. Waltenberger J, Kovalenko M, Böhmer F, Gazit A, Hombach V, Levitzki A. Characterization of receptor-tyrosine-kinase-inhibitors: selectivity as a molecular basis for the treatment of restenosis. Eur Heart J. 1994; 15(suppl):427. Abstract.
21. Banai S. Wolf Y, Golomb G, Pearle A, Waltenberger J, Fishbein I, Schneider A, Golomb G, Gazit A, Perez LS, Huber R, Lazarovichi G, Levitzki A, Gertz SD. PDGF-receptor tyrosine kinase blocker AG1295 selectively attenuates smooth muscle cell growth in vitro and reduces neointima formation after balloon angioplasty in swine. Circulation. 1998;97:1960-1969.
22. Claesson-Welsh L. Platelet-derived growth factor receptor signals. J Biol Chem. 1994;269:32023-32026.
23. Twamley SG, Pepperkok R, Ansorge W, Courtneidge SA. The Src family tyrosine kinases are required for platelet-derived growth factor-mediated signal transduction in NIH 3T3 cells. Proc Natl Acad Sci U S A. 1993; 90:7696-7700.
24. Erpel T, Courtneidge SA. Src family protein tyrosine kinases and cellular signal transduction pathways. Curr Opin Cell Biol. 1995;7:176-182. Review.
25. Mori S, Ronnstrand L, Yokote K, Engstrom A, Courtneidge SA, Claesson WL, Heldin CH. Identification of two juxtamembrane autophosphorylation sites in the PDGF β-receptor: involvement in the interaction with Src family tyrosine kinases. EMBO J. 1993;12:2257-2264.
26. Hansen K, Johnell M, Siegbahn A, Rorsman C, Engstrom U, Wernstedt C, Heldin CH, Ronnstrand L. Mutation of a src phosphorylation site in the PDGF β-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis. EMBO J. 1996;15:5299-5313.
27. Hanke JH, Gardner JP, Dow RL, Changelian PS, Brissette WH, Weringer EJ, Pollok K, Connelly PA. Discovery of a novel, potent, and src family-selective tyrosine kinase inhibitor: study of lck-dependent and fynt-dependent T-cell activation. J Biol Chem. 1996;271:695-701.
28. Betsholtz C, Raines EW. Platelet-derived growth factor: a key regulator of connective-tissue cells in embryogenesis and pathogenesis. Kidney Int. 1997;51:1361-1369.
29. Southwick PL, Dhawan B. Preparation of 4,6-diaminopyrazolo[3,4-d]pyrimidines with variation in substitution at the 1 and 3 positions. J Heterocyclic Chem. 1975;12:1199-1203.
30. Waltenberger J, Claesson-Welsh L, Siegbahn A, Shibuya M, Heldin C-H. Different signal transduction properties of KDR and Fltl, two receptors for vascular endothelial growth factor. J Biol Chem. 1994;269:26988-26995.
31. Westermark B, Siegbahn A, Heldin C-H, Claesson-Welsh L. B-type receptor for platelet-derived growth factor mediates a chemotactic response by means of ligand-induced activation of the receptor protein-tyrosine kinase. Proc Natl Acad Sci U S A. 1990;87:128-132.
32. Bjorge JD, Bellagamba C, Cheng HC, Tanaka A, Wang JH, Fujita DJ. J Biol Chem. 1995;270:24222-24228.
33. Claesson-Welsh L, Hammacher A, Westermark B, Heldin C-H, Nistér M. Identification and structural analysis of the A type receptor for platelet-derived growth factor: similarities with the B type receptor. J Biol Chem. 1989;264:1742-1747.
34. Songyang Z, Carraway KL, Eck MJ, Harrison SC, Feldman RA, Mohammadi M, Schlessinger J, Hubbard SR, Smith DP, Eng C, Lorenzo MJ, Ponder BAJ, Mayer BJ, Cantley LC. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995;373:536-539.
35. Waltenberger J, Mayr U, Pentz S, Hombach V. Functional upregulation of the vascular endothelial growth factor receptor KDR by hypoxia. Circulation. 1996;94:1647-1654.
36. Waltenberger J, Mayr U, Frank H, Hombach V. Suramin is a potent inhibitor of vascular endothelial growth factor: interaction with KDR as a potential molecular basis for its antiangiogenic action. J Mol Cell Cardiol. 1996;28:1523-1529.
37. Agbotounou WK, Levitzki A, Jacquemin SA, Pierre J. Effects of tyrphostins on the activated c-src protein in NIH/3T3 cells. Mol Pharmacol. 1994;45:922-931.
38. Uchida T, Matozaki T, Noguchi T, Yamao T, Horita K, Suzuki T, Fujioka Y, Sakamoto C, Kasuga M. Insulin stimulates the phosphorylation of Tyr(538) and the catalytic activity of Ptp1c, a protein tyrosine phosphatase with SRC homology-2 domains. J Biol Chem. 1994;269: 12220-12228.
39. Vambutas V, Kaplan DR, Sells MA, Chernoff J. Nerve growth factor stimulates tyrosine phosphorylation and activation of Src homology-containing protein-tyrosine phosphatase 1 in PC12 cells. J Biol Chem. 1995;270:25629-25633.
40. Vogel W, Lammers R, Huang J, Ullrich A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science. 1993;259: 1611-1614.
41. Banai S, Schneider A, Pearle A, Gertz SD, Golomb G, Levitzki A, Wolff Y. Effect of selective PDGF-receptor versus non-selective protein tyrosine kinase blockers on aortic SMCs and endothelial cells proliferation. J Am Coll Cardiol. 1996;27:255A. Abstract.
42. Sirois MG, Simons M, Edelman ER. Antisense oligonucleotide inhibition of PDGFR-β receptor subunit expression directs suppression of intimal thickening. Circulation. 1997;95:669-676.
43. Waltenberger J, Akyürek ML, Aurivillius M, Wanders A, Larsson E, Fellström B, Funa K. Ischemia-induced transplant arteriosclerosis in the rat: induction of peptide growth factor expression. Arterioscler Thromb Vasc Biol. 1996;16:1516-1523.